Calroy Health Sciences | 1-800-609-6409

Research papers are made available to registered licensed health care practitioners only.

Please Log In in order to view this content!

IMPORTANT NOTICE: The information on this webpage is for licensed healthcare practitioner education only, and is not to be disseminated to the general public.


A brief summary of studies of Arterosil, a specific glycocalyx regenerating compound (GRC) for the restoration of endothelial function and regression of atherosclerotic plaque.

Three types of studies are reported: cellular, animal and human. Each study focused on a different effect of Arterosil, a nutraceutical that contains a patent-pending endothelial glycocalyx regenerating compound (GRC).

Atherosclerotic Plaque Regression Study Hospital in Beijing — Human Pilot (still underway)
Preliminary Findings to Date: 47% and 64% regression of atherosclerotic plaque lipid-rich necrotic core (LRNC) in 60 days

These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure or prevent any disease.

U.S. and International Patents Pending